Tirzepatide

Tirzepatide/Niacinamide Injection is a compounded subcutaneous medication that combines tirzepatide, a dual incretin mimetic, with niacinamide (vitamin B3). Tirzepatide acts as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating both pathways, it enhances insulin secretion and decreases glucagon release in response to elevated blood glucose, helping to improve glycemic control and support weight management.

Niacinamide, also known as nicotinamide, is a water-soluble form of vitamin B3 included in this formulation for its metabolic and stabilizing properties. It functions as a precursor to coenzymes involved in energy production and supports cellular processes throughout the body. Vitamin B3 plays a role in digestion, nerve function, and skin health, and is essential for converting nutrients into usable energy. In this combination, niacinamide contributes to overall metabolic support while also helping maintain formulation integrity. At a modest dose of 2 mg/mL, it acts as a cofactor without producing the flushing effects associated with higher-dose niacin therapies.

Tirzepatide/Niacinamide Injection is available in multiple strengths to support individualized dosing. The formulation is provided in 17 mg/2 mg per mL and 8 mg/2 mg per mL concentrations, with various vial sizes for flexibility in use. Treatment with tirzepatide typically begins at a low dose and is gradually increased based on patient response and tolerability. This medication is administered as a once-weekly subcutaneous injection. The addition of niacinamide does not alter the dosing schedule.

This product is intended for use under the supervision of a licensed healthcare provider and should be used only with a valid prescription as part of a broader plan for managing blood sugar and weight.